PACTR201901529431463
Completed
Phase 4
Evaluation of the Efficacy and Safety of Sublingual Immunotherapy ( Traditional Coca’s extract) in the treatment of Allergic Rhinoconjunctivitis
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Ear, Nose and Throat
- Sponsor
- Faculty of Medicine Zagazig University
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adolescent or adult Patient with a history of moderate to severe chronic allergic rhinoconjunctivitis without any co\-morbidities.
Exclusion Criteria
- •The study excluded any patient with active, acute, or chronic obstructive pulmonary disease, except for asthma and allergic rhinitis; forced expiratory volume in 1 s \= 70% of predicted value;
- •Patients who have disorders concerning drug absorption, distribution, metabolism, and excretion.
- •Inability to perform Skin prick test in patients included in group 2\.
- •Illiterate patients who cannot read the self\-administered quality of life questioner were also excluded.
- •Refusal of consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of the efficacy and safety of luseogliflozin and changes in QOType 2 diabetes mellitusJPRN-UMIN000023035The Institute for Adult Diseases, Asahi Life Foundation64
Completed
Phase 2
Squalene for COVID-19 treatmentCOVID-19.COVID-19, virus identifiedU07.1IRCT20200927048848N3Mashhad University of Medical Sciences200
Completed
Phase 4
The evaluation of the efficacy and safety of oral fingolimod in relapsing remitting multiple sclerosismultiple sclerosis.Disseminated Multiple SclerosisIRCT201406018323N10Vice-chancellor for research, Kermanshah University of Medical Sciences60
Completed
Phase 1
A trial to evaluate an oral medicinal cannabis extract compared with placebo for the treatment of insomnia.InsomniaNeurological - Other neurological disordersACTRN12618000078257Zelda Therapeutics Limited24
Completed
Phase 2
Sublingual immunotherapy with VALERGEN-Asthma-Children-Phase IIAsthmaRPCEC00000125ational Center of Bioproducts (BioCen)300